5-allyloxy-1-phenylbenzimidazole hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 5-allyloxy-1-phenylbenzimidazole hydrochloride
• 英文别名: 1-Phenyl-5-prop-2-enoxybenzimidazole;hydrochloride
• 化学式: C₁₆H₁₄N₂O*ClH
• 分子量: 286.761
• InChiKey: ATRJLYLQTPIBRQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.01
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  27
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-allyloxy-1-phenylbenzimidazole hydrochloride 以 异丙醇 为溶剂， 反应 24.0h， 以100%的产率得到4-Allyl-1-phenyl-1H-benzoimidazol-5-ol
  参考文献：
  名称：

  Structure−Activity Relationships for 5-Substituted 1-Phenylbenzimidazoles as Selective Inhibitors of the Platelet-Derived Growth Factor Receptor

  摘要：

  Following an earlier discovery of 1-phenylbenzimidazoles as ATP-site inhibitors of the platelet-derived growth factor receptor (PDGFR), further structure-activity relationships for analogues (particularly 5-substituted derivatives) are reported. The data are consistent with a binding model (constructed from the homology-modeled structure of the catalytic subunit of the PDGFR using protein kinase A as the template) in which the ligand binds in the relatively narrow ATP site, with the phenyl ring pointing toward the interior of the pocket and the 5-position of the benzimidazole ring toward the mouth of the pocket. The narrow binding pocket allows a maximum torsion angle between the phenyl and benzimidazole rings of about 40 degrees, consistent with that calculated (43.6 degrees) for the minimum-energy conformation of the unsubstituted free ligand. The inactivity of 7- or 2'-substituted analogues is consistent with the greater torsion angle (and thus larger ligand cross-section) of such substituted analogues. There is substantial bulk tolerance for 5-substituents, which protrude out of the mouth of the hydrophobic pocket, with the most effective analogues being those bearing weak bases. On the basis of this model, 5-OR derivatives bearing cationic side chains were prepared as soluble analogues, and these showed sub-micromolar potencies against the isolated PDGFR enzyme. They were also moderately effective inhibitors of autophosphorylation of PDGFR in rat aortic vascular smooth muscle cells, with IC(50)s in the range 0.1-1 mu 1M.

  DOI：

  10.1021/jm980658b
• 作为产物：
  描述：

  1-苯基-5-羟基苯并咪唑 、 3-溴丙烯 生成 5-allyloxy-1-phenylbenzimidazole hydrochloride
  参考文献：
  名称：

  Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular

  摘要：

  下面的I式苯并咪唑是蛋白酪氨酸激酶的抑制剂，对治疗细胞增殖很有用。这些化合物在治疗癌症、动脉粥样硬化、再狭窄和牛皮癣方面特别有效。

  公开号：

  US05990146A1

文献信息

• N-ACYLAMINO ACID AMIDE COMPOUNDS AND INTERMEDIATES FOR PREPARATION THEREOF
  申请人：UBE INDUSTRIES LIMITED

  公开号：EP1020467A1

  公开（公告）日：2000-07-19

  The present invention discloses the compound represented by the formula (I): wherein A represents the following formula (a-1) or the following formula (a-2): B represents the following formula (b): (wherein the symbols are each as defined in the specification) or a pharmaceutically acceptable salts thereof, and intermediates for the preparation thereof, which have excellent platelet aggregation inhibitory activity and other properties and useful as prophylactic or therapeutic agents for diseases associated with a fibrinogen receptor, thrombosis, infarction and the like.

  本发明公开了式 (I) 所代表的化合物： 其中 A 代表下式（a-1）或下式（a-2）： B 代表下式（b）： (其中各符号如说明书中所定义）或其药学上可接受的盐类，以及用于制备它们的中间体，它们具有优异的血小板聚集抑制活性和其他特性，可用作与纤维蛋白原受体、血栓形成、梗塞等相关疾病的预防或治疗药物。
• US5990146A
  申请人：——

  公开号：US5990146A

  公开（公告）日：1999-11-23
• US6218388B1
  申请人：——

  公开号：US6218388B1

  公开（公告）日：2001-04-17
• US6265418B1
  申请人：——

  公开号：US6265418B1

  公开（公告）日：2001-07-24
• Structure−Activity Relationships for 5-Substituted 1-Phenylbenzimidazoles as Selective Inhibitors of the Platelet-Derived Growth Factor Receptor
  作者：Brian D. Palmer、Alan J. Kraker、Brian G. Hartl、Athanasia D. Panopoulos、Robert L. Panek、Brian L. Batley、Gina H. Lu、Susanne Trumpp-Kallmeyer、H. D. Hollis Showalter、William A. Denny

  DOI：10.1021/jm980658b

  日期：1999.7.1

  Following an earlier discovery of 1-phenylbenzimidazoles as ATP-site inhibitors of the platelet-derived growth factor receptor (PDGFR), further structure-activity relationships for analogues (particularly 5-substituted derivatives) are reported. The data are consistent with a binding model (constructed from the homology-modeled structure of the catalytic subunit of the PDGFR using protein kinase A as the template) in which the ligand binds in the relatively narrow ATP site, with the phenyl ring pointing toward the interior of the pocket and the 5-position of the benzimidazole ring toward the mouth of the pocket. The narrow binding pocket allows a maximum torsion angle between the phenyl and benzimidazole rings of about 40 degrees, consistent with that calculated (43.6 degrees) for the minimum-energy conformation of the unsubstituted free ligand. The inactivity of 7- or 2'-substituted analogues is consistent with the greater torsion angle (and thus larger ligand cross-section) of such substituted analogues. There is substantial bulk tolerance for 5-substituents, which protrude out of the mouth of the hydrophobic pocket, with the most effective analogues being those bearing weak bases. On the basis of this model, 5-OR derivatives bearing cationic side chains were prepared as soluble analogues, and these showed sub-micromolar potencies against the isolated PDGFR enzyme. They were also moderately effective inhibitors of autophosphorylation of PDGFR in rat aortic vascular smooth muscle cells, with IC(50)s in the range 0.1-1 mu 1M.